GenVec has announced that it will collaborate with a division of pharmaceutical powerhouse Sanofi-Aventis SA on the development of a new form of foot-and-mouth disease vaccines. Want to know more on what this development means for you and your health, keep on reading after the jump.
GenVec is teaming up with Merial, the animal health division of Sanofi-Aventis SA, on the development of a new kind of vaccination for foot-and-mouth disease.
Commonly found in hoofed animals, this disease can be passed onto humans, though it is fairly rare. However, with the outbreaks of human forms of swine flu and bird flu in recent years, as well as foot-and-mouth epidemics in parts of Asia, any new advancement should be looked at as a positive step forward.
Merial is already the world leader in food-and-mouth disease vaccines, and will foot the bill for the development and commercialization of the new vaccine, while GenVec will receive royalties and milestone payments for the use of their technology.
Though there are already several foot-and-mouth disease vaccines available, this new development is particularly interesting and vital to how vaccines may be developed in the future. The new vaccine will be developed without the use of a live or killed virus the way many vaccines are currently developed.
Whether or not this new vaccine and vaccine development technology will change the way vaccines are made is yet to be seen, but if GenVec and Merial are successful in their development it may have a significant impact on vaccine development.
What do you think of the development of this foot-and-mouth vaccine without the use of a live or killed virus? Do you think it will have an impact on the way medication, especially vaccines are developed in the future? Leave us some comments and let us know, and be sure to check out this video on the topic below.